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Abstract
Oral administration of nucleotide analogues and injection of interferon-α (IFNα) are used to
achieve immediate suppression in replication of hepatitis B virus (HBV). Nucleotide analogs
and IFNα inhibit viral polymerase activity and cause long-term eradication of the virus at
least in part through removing covalently closed circular DNA (cccDNA) via induction of the
APOBEC3 deaminases family of molecules, respectively. This study aimed to explore
whether the orally administrable low molecular weight agent CDM-3008 (RO8191), which
mimics IFNα through the binding to IFNα/β receptor 2 (IFNAR2) and the activation of the
JAK/STAT pathway, can suppress HBV replication and reduce cccDNA levels. In primary
cultured human hepatocytes, HBV DNA levels were decreased after CDM-3008-treatment
in a dose-dependent manner with a half-maximal inhibitory concentration (IC50) value of
0.1 μM, and this was accompanied by significant reductions in cellular cccDNA levels, both
HBeAg and HBsAg levels in the cell culture medium. Using a microarray we comprehen-
sively analyzed and compared changes in gene (mRNA) expression in CDM-3008- and
IFNα-treated primary cultured human hepatocytes. As reported previously, CDM-3008 mim-
icked the induction of genes that participate in the interferon signaling pathway. OAS1 and
ISG20 mRNA expression was similarly enhanced by both CDM-3008 and IFNα. Thus,
CDM-3008 could suppress pgRNA expression to show anti-HBV activity. APOBEC3F and
3G mRNA expression was also induced by CDM-3008 and IFNα treatments, suggesting
that cccDNA could be degraded through induced APOBEC3 family proteins. We identified
the genes whose expression was specifically enhanced in CDM-3008-treated cells com-
pared to IFNα-treated cells. The expression of SOCS1, SOCS2, SOCS3, and CISH, which
inhibit STAT activation, was enhanced in CDM-3008-treated cells suggesting that a feed-
back inhibition of the JAK/STAT pathway was enhanced in CDM-3008-treated cells
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compared to IFNα-treated cells. In addition, CDM-3008 showed an additive effect with a clin-
ically-used nucleoside entecavir on inhibition of HBV replication. In summary, CDM-3008
showed anti-HBV activity through activation of the JAK/STAT pathway, inducing the expres-
sion of interferon-stimulated genes (ISGs), with greater feedback inhibition than IFNα.
Introduction
More than 200 million people are chronically infected with hepatitis B virus (HBV) worldwide
[1–3]. HBV is associated with the development of hepatocellular carcinoma (HCC) through
progression of cirrhosis [4–6]. Thus, drug development for the elimination of HBV is urgently
need.
HBV virions contain partially double-stranded relaxed circular DNA (rcDNA). After inter-
nalization into hepatocytes, rcDNA is converted into covalently closed circular DNA
(cccDNA) using an intracellular DNA repair mechanism, and cccDNA then starts transcrip-
tion of pregenomic RNA (pgRNA) and mRNAs for surface antigen, capsid, polymerase, and X
protein. pgRNA is reverse-transcribed by polymerase in the capsid, and HBV virions are then
released after being coated with surface antigen [7].
Nucleotide analogs are mainly used to suppress HBV replication, but these drugs cannot
completely remove cccDNA and pose a risk of drug resistance [8–10]. Interferon-α (IFNα)
treatment induces interferon-stimulated genes (ISGs) through activation of the janus kinase/
signal transducers and activators of transcription (JAK/STAT) signaling pathway and shows
anti-HBV activity mainly through RNase L activity for suppression of pgRNA [11–13],
although IFNα is associated with several side effects and induces hepatitis B e antigen
(HBeAg) seroconversion in approximately 30% of chronically infected HBV patients [14,15].
Proteins of the apolipoprotein B mRNA-editing enzyme catalytic polypeptide–like 3 (APO-
BEC3) family have recently been reported to trigger the degradation of cccDNA through their
deaminase activity stimulated by IFNα, IFNγ, lymphotoxinβ, and TNFα [16,17]. Because
cccDNA can be degraded after IFN administration, development of IFN-based drugs is impor-
tant for complete cure in case of HBV infection. Cotreatment with an orally available IFN-
based drug and nucleotides/nucleosides could effectively suppress HBV. Poly(I:C) and
GS9620, Toll-like receptor agonists, have been reported to exert anti-HBV activity through
IFN expression [18,19]. To directly induce ISGs and reduce side effects, the development of
IFN-based small compounds is desirable.
As the first step to improve anti-HBV activity and reduce the side effects of IFNα [20], we
focused on a small chemical compound, RO8191, which functions as an IFNα/β receptor 2
(IFNAR2) agonist. RO8191 binds to IFNAR2 and it induces ISG expression through the JAK/
STAT signaling pathway, and showing anti-hepatitis C virus activity [21]. RO8191 can be
administrated orally and produced at a low cost and thus has an advantage over IFNα, which
must be injected [21]. In this study, we discovered that RO8191 has anti-HBV activity and
modulates cccDNA levels through interferon-like activity. Thus, we named RO8191 as a
cccDNA modulator (CDM) and numbered it 3008. To further understand the molecular basis
of the anti-HBV activity of CDM-3008, we compared the activities of CDM-3008 and IFNα on
gene expression pattern in human primary hepatocytes using a microarray.
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Materials and methods
Culture of primary human hepatocytes (PXB cells) isolated from chimeric
mice with humanized livers
PXB cells were purchased from PhoenixBio and cultured on collagen type I-coated 96 well or
24 well plates in hepatocyte clonal growth medium (dHCGM) under 37˚C and 5% CO2 as pre-
viously described [22].
Assay of anti-HBV activity using PXB cells
PXB cells were infected with 3 genome equivalents per cell of HBV C_AT [23], and the
medium was exchanged every 3 or 4 days. After 28 days of infection, CDM-3008 was serially
diluted in DMSO from 0.03–10 μM and mixed with dHCGM, and the cells were then treated
with a final concentration of 0.0003–100 μM CDM-3008 for 7 days.
After infection and treatments, the cell culture medium was collected, and cell viability was
measured using the RealTime-Glo MT Cell Viability Assay (Promega). Cellular DNA was then
purified using the Agencourt DNAdvance System (Beckman Coulter).
MT cell viability assay
After treatment with compounds, cell viability was measured using the RealTIme-Glo MT Cell
Viability Assay (Promega) according to the manufacturer’s instructions. The cells were incu-
bated with 95 μl of cell culture medium, 2.5 μl of MT Cell Viability Substrate, and 2.5 μl of
NanoLuc Enzyme under 5% CO2 at 37 ˚C for 60 min. To detect luminescence, 50 μl of the
medium was transferred to 96-well white plates (3912, Costar), and luminescence intensity
was measured using a multi-mode plate reader (EnSight, PerkinElmer).
XTT assay
After treatment with compounds, cell viability was measured using the Cell Proliferation Kit II
(Roche) according to the manufacturer’s instructions. The cells were incubated with 100 μl of
cell culture medium and 50 μl of XTT reagent (Cell Proliferation Kit II, Roche) under 5% CO2
at 37 ˚C for 45 min. The absorbance at 492 nm was then measured using a multi-mode plate
reader (EnSight, PerkinElmer).
Knockdown of IFNAR2
IFNAR2 siRNA (siGENOME SMART pool Human IFNAR2, M-015411-00, Dharmacon) or
control siRNA (siGENOME Control pool Nontargeting #1, D-001206-13-05, Dharmacon)
were mixed with Dharma FECT 4 in OPTI-MEM (Thermo), and HCV replicon cells were
then mixed with the siRNA and plated in 96 well plates. After 2 days of incubation, the cells
were treated with 30 μM CDM-3008 for 8 h. Total RNA was purified from the cells using
Agencourt RNAdvance (Beckman).
IFNβ-treatment after incubation with CDM-3008 or IFNα
PXB cells were treated with 30 μM CDM-3008 or 10 ng/ml PEGylated IFNα2a (Pegasys, Chu-
gai pharmaceutical) for 24 h followed by treatment with 10 ng/ml recombinant IFNβ (Wako)
for 4 h. Total RNA was purified from the cells using Agencourt RNAdvance Cell v2
(Beckman).
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DNA purification from cultured cells
After treatment with compounds, DNA was automatically purified using the Agencourt
DNAdvance Genomic DNA Isolation Kit and an automatic dispenser (Biomek i5 or NXp,
Beckman Coulter) according to the manufacturer’s instructions. Briefly, the cells were washed
3 times with PBS and incubated with 200 μl of Lysis buffer containing 50 mM dithiothreitol
(DTT) and proteinase K at 55 ˚C for 1 h with constant agitation. The lysates were transferred
to 96-well 1.2-ml deep well storage plates (Thermo, AB1127) and mixed with 100 μl of Bind1
buffer, and then the 170 μl of Bind2 buffer was then added, and the samples were again mixed.
After collection of the DNA-binding magnetic beads, the beads were washed twice with 340 μl
of 70% ethanol. DNA was eluted with 200 μl of MilliQ water.
DNA purification from cell culture medium
After collection of the cell culture medium, the DNA present in the medium was automatically
purified using Agencourt Genfind v2 and an automatic dispenser (Biomek i5 or NXp, Beckman
Coulter) according to the manufacturer’s instructions. Briefly, 50 μl of cell culture medium was
mixed with 200 μl of Lysis buffer containing Proteinase K in a 96-well 1.2-ml deep-well storage
plate (Thermo, AB1127); the mixture was then incubated at 37 ˚C for 3 h with constant agita-
tion. After centrifugation at 1,000xg for 1 min, 150 μl of Binding buffer was added to the lysates
and mixed. The DNA-binding magnetic beads were washed twice with 400 μl of Wash buffer 1
and twice with 250 μl of Wash buffer 2. DNA was eluted with 50 μl of MilliQ water.
RNA purification from cultured cells
RNeasy mini kit (Qiagen) for RNA purification from cells cultured in 24-well plates.
After washing the cells with PBS 3 times, RNA purification was performed using the RNeasy
mini kit (Qiagen) according to the manufacturer’s instructions.
Agencourt RNAdvance Cell v2 (Beckman Coulter) for RNA purification from cells cul-
tured in 96-well plates. RNA purification was automatically performed using Agencourt
RNAdvance Cell v2 and an automatic dispenser (Biomek i5 or NXp, Beckman Colter) accord-
ing to the manufacturer’s instructions. The cells were washed 3 times with PBS and then incu-
bated with 63 μl of Lysis buffer containing proteinase K at 25 ˚C for 30 min and stored at -80
˚C. After thawing and centrifugation at 1,000xg for 15 s, 175 μl of Binding buffer solution was
mixed with the lysates in a 96-well 1.2-ml deep-well storage plate (Thermo, AB1127). The
RNA-binding magnetic beads were washed with 200 μl of Wash buffer followed by 200 μl of
70% ethanol and then incubated with 5 U DNaseI (Nippon gene) at 25 ˚C for 15 min. The
beads were then washed once with 138 μl of Wash buffer and twice with 200 μl of 70% ethanol.
RNA was eluted with 40 μl of MilliQ water (RNase and DNase free).
T5 exonuclease treatment
T5 exonuclease treatment was performed according to the method described previously [24].
Briefly, 89 μl of purified DNA using an Agencourt DNAdvance Genomic DNA Isolation Kit
was treated with 10 U of T5 exonuclease (New England Biolabs) at 37 ˚C for 1 h, and T5 exo-
nuclease was inactivated at 70 ˚C for 20 min. DNA was ethanol-precipitated and redissolved in
5 μl of 10 mM Tris/HCl pH 7.5 containing 1 mM EDTA.
qPCR analysis of HBV DNA and cccDNA
HBV DNA and cccDNA copy numbers were determined using TaqMan Gene Expression
Master Mix (Thermo Fisher) or Probe qPCR Mix (Takara), specific primers, and probes in a
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quantitative PCR system (Light Cycler96, Roche or CFX-96, Bio-rad). The specific primers
and probes used for detection of HBV DNA were shown (forward primer: 5’-ACTCACCA
ACCTCCTGTCCT-3’, reverse primer: 5’-GACAAACGGGCAACATACCT-3’, and probe:
5’-[FAM] TATCGCTGGATGTGTCTGCGGCGT[TAM]-3’). The specific primers and
probes used for detection of cccDNA were developed by Qu et al. [24] and designed for HBV
C_AT (forward primer: 5’-GTGGCTATCCTGCCTTAAT-3’, reverse primer: 5’-CAGA
GCTGAGGCGGTGTC-3’, and probe: 5’-[FAM] AGTTGGCGAGAAAGTGAAAGCCTGC
[TAM]-3’).
qPCR analysis of ISGs induction
ISGs mRNA expression levels were measured by qPCR using specific primers or sets of specific
primers and probe. RNA was reverse transcribed using PrimeScript RT Master Mix (Takara) to
synthesize cDNA. IFNAR1 and IFNAR2 mRNA levels were measured using sets of specific
primers and probes (Hs01066116 m1 IFNAR1 and Hs01022059 m1 IFNAR2, Applied Biosys-
tems) and Probe qPCR mix (Takara) in a Light Cycler 96 qPCR system (Roche). STAT2, ISG15,
ISG20, USP18, SOCS1, SOCS2, SOCS3, CISH, APOBEC3F, APOBEC3G, SLPI, WFDC2, and
GAPDH mRNA expression levels were measured using specific primers and TB Green Premix
Ex Taq II (Takara) in a Light Cycler 96 qPCR system (Roche). The specific primers used in this
study were ISG15 (forward primer: 5’ TCCTGGTGAGGAATAACAAGGG-3’, reverse primer:
5’- GTCAGCCAGAACAGGTCGTC-3’), ISG20 (forward primer: 5’-TAGCCGCTCATG
TCCTCTTT-3’, reverse primer: 5’-TGAGGGAGAGATCACCGATT-3’), USP18 (forward
primer: 5’- CCTGAGGCAAATCTGTCAGTC-3’, OAS1 (forward primer: 5’- TCCGTGA
AGTTTGAGGTCCA-3’, reverse primer: 5’- ATCAAAGGCAGGCAGCACAT-3’), reverse
primer: 5’- CGAACACCTGAATCAAGGAGTTA-3’), SOCS1 (forward primer: 5’-GCCCC
TTCTGTAGGATGGTA-3’, reverse primer: 5’-CTGCTGTGGAGACTGCATTG-3’), SOCS2
(forward primer: 5’-ATGACCCTGCGGTGCCT-3’, reverse primer: 5’-AAAGTTCCTTC
TGGTGCCTCT-3’), STAT2 (forward primer: 5’-CATACTAGGGACGGGAAGTCG-3’,
reverse primer: 5’-ATTCTGCAGCATTTCCCACT-3’), SOCS3 (forward primer: 5’-CTT
CGACTGCGTGCTCAA-3’, reverse primer: 5’-GTAGGTGGCGAGGGGAAG-3’), STAT2 (for-
ward primer: 5’-CATACTAGGGACGGGAAGTCG-3’, reverse primer: 5’-ATTCTGCAGCA
TTTCCCACT-3’), CISH (forward primer: 5’- TTCTGCACTCAGGGAGGACT-3’, reverse
primer: 5’-CAGGAGGAAGGAACTTGCTG-3’), APOBEC3F (forward primer: 5’-CCGTT
TGGACGCAAAGAT-3’, reverse primer: 5’-CCAGGTGATCTGGAAACACTT-3’), APO-
BEC3G (forward primer: 5’-CCGAGGACCCGAAGGTTAC-3’, reverse primer: 5’-TCCAA
CAGTGCTGAAATTCG-3’), SLPI (forward primer: 5’-GAGATGTTGTCCTGACACTT
GTG-3’, reverse primer: 5’-AGGCTTCCTCCTTGTTGGGT-3’), WFDC2 (forward primer:
5’-CGGCTTCACCCTAGTCTCAG-3’, reverse primer: 5’-CCTCCTTATCATTGGGC
AGA-3’) and GAPDH (forward primer: 5’-CAATGACCCCTTCATTGACC-3’, reverse
primer: 5’-GACAAGCTTCCCGTTCTCAG-3’).
Measurement of hepatitis B antigens
Hepatitis B s antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels in the cell culture
medium were measured using Enzygnost HBsAg 6.0 and Enzygnost HBe monoclonal (Sie-
mens), respectively, according to the manufacturer’s instructions.
3D-PCR detection of APOBEC3 activity
PXB cells were infected with 3 genome equivalents per cell of HBV C_AT [23], and the
medium was exchanged every 3 or 4 days. After 28 days of infection, the cells were treated with
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100 μM CDM-3008 and 10,000 IU/ml IFNα (Sumitomo Dainippon Pharma) in dHCGM for 7
days. After infection and treatments, the cellular DNA was then purified using the Agencourt
DNAdvance System (Beckman Coulter). 3D-PCR was performed according to standard hepa-
titis B virus methods and protocols [25]. Briefly, cccDNA was amplified from the purified
DNA by PCR (PCR Thermal Cycler Dice Touch, Takara) using specific primers designed for
HBV C_AT sequence (forward primer: 5’-AGAGCTGAGGCGGTGTCGAG-3’, reverse
primer: 5’-ACCTATTGATTGGAAAGTATGT-3’) and KOD One PCR Master Mix (Toyobo).
The HBx region was amplified by nested PCR using specific primers (forward primer: 5’-
ATGGCTGCTARGCTGTGCTGCCAA-3’, reverse primer: 5’-AAGTGCACACGGTYYGGC
AGAT-3’) and KOD One PCR Master Mix (Toyobo) with gradient of denaturation tempera-
ture (80–92 ˚C). The nested PCR products were separated by 2% agarose gel electrophoresis,
visualized with ethidium bromide, subcloned using the Zero Blunt TOPO PCR cloning kit
(Thermo Fisher), and sequenced using the BigDye Terminator v3.1 sequencing kit (Thermo
Fisher).
Microarray analysis
PXB cells cultured in 24-well plates were not infected or were infected with 3 genome equiva-
lents per cell of HBV C_AT. After 30 days of infection, the cells were treated with 30 μM
CDM-3008 and 10 ng/ml PEGylated IFNα2a (Pegasys, Chugai pharmaceutical) for 4 and 8 h
(n = 3). Following treatments, total RNA was purified from the cells using an RNeasy mini kit
(Qiagen). The amount of total RNA was measured using a NanoDrop ND-1000 (NanoDrop
Technologies). Microarray analysis was performed using the Illumina platform. Five hundred
nanograms of total RNA was used for first-stranded cDNA and second-stranded cRNA prepa-
ration with the Illumina TotalPrep RNA Amplification Kit (Ambion, USA). The converted
cRNA was then labeled and hybridized using the Human HT-12 v4 Expression BeadChip Kit
according to the manufacturer’s instruction. Experimental triplicate samples were prepared
for microarray analysis, and the data were processed with a package from Bioconductor (lumi)
using a free software environment, R (http://www.r-project.org/). The raw and normalized
data were uploaded to NCBI Gene Expression Omnibus (GSE126090).
Knowledge-based pathway analysis
To explore the biological interpretation of the transcriptome data, the canonical pathway was
identified using knowledge-based functional analysis software from Ingenuity Pathways Anal-
ysis (IPA; Ingenuity Systems).
Statistical analysis
Student’s t-test was performed to compare mean using Microsoft Excel 2013.
Results
Anti-hepatitis C virus (HCV) activity of CDM-3008 was previously reported by Konishi et al.
[21], but anti-HBV activity of CDM-3008 was remain unknown. To demonstrate the anti-
HBV activity of CDM-3008 whose chemical structure is shown in Fig 1A, primary cultured
human hepatocytes (PXB cells) were infected with HBV genotype C and cultured for 28 days.
Then, the cells were treated with serially diluted CDM-3008 for 7 days (Fig 1B). HBV DNA
was decreased in the cells upon CDM-3008 treatment in a dose-dependent manner (Fig 1C).
The IC50 for inhibition of cellular HBV DNA was calculated as 0.1 μM. cccDNA in the cells,
CDM-3008 suppresses hepatitis B virus
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Fig 1. Anti-HBV activity of CDM-3008 in primary cultured human hepatocytes. (A) The chemical structure of CDM-3008. (B) The schematic
experimental design of the anti-HBV activity analysis. Primary cultured human hepatocytes (PXB cells) were infected with HBV genotype C for
1day (green) and cultured for 28 days, and the cells were then treated with 0–100 μM CDM-3008 for 7 days (magenta). The black triangles show the
time points of medium changes. (C) Measurement of HBV DNA copies in PXB cells after 7 days of CDM-3008 treatment. HBV DNA was decreased
with 0.1–100 μM CDM-3008 in a dose-dependent manner. (D) Measurement of cccDNA copies after T5 exonuclease treatment. cccDNA was
significantly decreased with 10–100 μM CDM-3008. Error bars indicate S.D. in D (n = 3). �, p< 0.05 (one-tailed t-test) in D. (E) HBsAg levels are
CDM-3008 suppresses hepatitis B virus
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HBeAg and HBsAg in the medium were also significantly decreased with CDM-3008 treat-
ment (Fig 1D–1F) without showing dose-dependent cytotoxicity (Fig 1G).
Konishi et al. reported that CDM-3008 induced ISGs expression and suppressed HCV rep-
licon through IFNAR2 [21]. To show that anti-HBV activity was mainly regulated by ISGs
expression through IFNAR2, we analyzed 2’-5’-oligoadenylate synthase 1 (OAS1) expression
after knockdown of IFNAR2. However, knockdown of IFNAR2 in PXB cells did not work by
unknown reason. Thus, knockdown of IFNAR2 was performed in HCV replicon cells instead
of in PXB cells. Induction of OAS1 was suppressed by knockdown of IFNAR2 (Fig 2A–2C).
Thus, CDM-3008 induced ISGs expression through IFNAR2 activation.
To confirm that CDM-3008’s anti-HBV activity was mediated mainly through ISGs and
not through inhibition of HBV replication, anti-HBV activity was measured in Hep38.7-Tet
cells [26]. Because HepG2-derived cells are relatively defective in ISGs expression, IFN does
not suppress HBV replication in Hep2.2.15 and HepAD38 cells [27,28]. The IC50 of CDM-
3008-induced anti-HBV activity in Hep38.7-Tet cells was more than 100 μM and compound
did not show cytotoxicity (Fig 3A–3C). The IC50 in Hep38.7-Tet cells was at least 100 times
higher than the IC50 in PXB cells. Thus, we speculated that the anti-HBV activity of CDM-
3008 was mainly due to the induced anti-virus activity of ISGs.
To determine the molecular mechanism of the anti-HBV activity of CDM-3008, PXB cells
were infected with HBV genotype C and cultured for 30 days, and the cells were then treated
with 30 μM CDM-3008 or 10 ng/ml IFNα for 4 h and 8 h (Fig 4A). The concentrations of
CDM-3008 and IFNα for microarray analysis in PXB cells were shown by qPCR to induce the
same expression levels of OAS1 mRNA, which is most abundantly induced by CDM-3008
treatment within ISGs in HCV replicon cells [21], at 4 h of treatments (Fig 4B). Total RNA was
purified from the cells and mRNA expression levels were comprehensively analyzed by micro-
array analysis. Genes that were significantly upregulated or downregulated more than 1.2-fold
in CDM-3008 and IFNα-treated cells compared to DMSO-treated cells were quantified (Fig
4C). Within 4 h of IFNα treatment, 4 and 170 genes were downregulated and upregulated,
respectively. Within 8 h of IFNα treatment, 5 and 182 genes were downregulated and upregu-
lated, respectively. Within 4 h of CDM-3008-treatment, 98 and 257 genes were downregulated
and upregulated, respectively. Within 8 h of CDM-3008-treatment, 83 and 245 genes were
downregulated and upregulated, respectively. At 4 h, 46 and 64 genes were significantly upre-
gulated and downregulated more than 1.2-fold, respectively, in CDM-3008-treated cells com-
pared to IFNα-treated cells; at 8 h, 48 and 88 genes were upregulated and downregulated,
respectively (Fig 4C). These results suggest that number of genes induced by CDM-3008 was
higher than the number induced by IFNα at 4 h and 8 h. Genes whose expression was upregu-
lated or downregulated by more than 1.2-fold in HBV-infected cells compared to non-infected
cells were quantified. No genes were upregulated or downregulated after 4 h or 8 h of control
(DMSO) treatment. The top 10 canonical pathways that were activated by IFNα and CDM-
3008 using the IPA program revealed that cellular signaling pathways were similarly respon-
sive to both treatments; the activation levels of the interferon signaling pathway were particu-
larly similar (Fig 4D).
To focus on the differences between IFNα and CDM-3008 in interferon signaling, the
expression ratios of genes in the interferon signaling pathway were analyzed using the IPA
program. The expression ratios at 4 h and 8 h of treatment with IFNα and CDM-3008 were
shown as fold changes. HBsAg levels were significantly decrease with 10–100 μM CDM-3008. (F) HBeAg levels are shown as fold changes. HBeAg
levels were significantly decreased with 0.1–100 μM CDM-3008. (G) Cell viabilities were shown as % of control DMSO. Error bars indicate S.D. in
C, E-G (n = 3). �, p< 0.05 and ��, p< 0.01 (two-tailed t-test) in C, E-G.
https://doi.org/10.1371/journal.pone.0216139.g001
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not significantly different for 14 of the 15 differentially expressed genes shown in the heat map
(Fig 5A). However, suppressor of cytokine signaling 1 (SOCS1), which inhibits STAT activa-
tion, was upregulated by CDM-3008-treatment at 8 h (Fig 5A), suggesting that feedback inhi-
bition of interferon signaling is strongly induced by CDM-3008 treatment compared with
Fig 2. Suppression of ISGs expression after knockdown of IFNAR2. HCV replicon cells were treated with IFNAR2 siRNA for 2 days
and incubated with CDM-3008 for 8 h. (A) IFNAR1 expression after control and IFNAR2 siRNA treatment. IFNAR1 expression was
not suppressed by IFNAR2 siRNA treatment. (B) IFNAR2 expression after control and IFNAR2 siRNA treatment. IFNAR2 mRNA
expression was suppressed by treatment with IFNAR2 siRNA but not by treatment with control siRNA. (C) OAS1 expression after
control and IFNAR2 siRNA treatment. OAS1 mRNA expression was suppressed by treatment with IFNAR2 siRNA but not by
treatment with control siRNA. The error bars in A-C indicate S.D. (n = 3). �, p< 0.05; ��, p< 0.01 (two-tailed t-test) in A-C.
https://doi.org/10.1371/journal.pone.0216139.g002
Fig 3. Analysis of anti-HBV activity in HepG2-derived cells. (A) Schematic experimental design of the anti-HBV activity analysis. Hep38.7-Tet cells
were cultured for 1 day; the cells were then treated with 0–100 μM CDM-3008 for 6 days (magenta). The black triangles show the times at which the
medium was changed. (B, C) Hep38.7-Tet cells were treated with serially diluted CDM-3008 (0–100 μM) for 6 days. After 6 days of treatment, the HBV
DNA levels in the cell culture medium were measured by qPCR (B), and cell viability was measured by XTT assay (C). The error bars in B, C indicate S.
D. (n = 3).
https://doi.org/10.1371/journal.pone.0216139.g003
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Fig 4. Microarray analysis of mRNA expression after CDM-3008 treatment. (A) Schematic of the experimental
design of HBV infection and IFNα and CDM-3008 treatment prior to microarray analysis. PXB cells were infected
with HBV genotype C for 1 day (green) and cultured for 30 days. The cells were then treated with 10 ng/ml IFNα or
30 μM CDM-3008 for 4 h or 8 h (magenta). The black triangles show the times at which the medium was changed. (B)
Analysis of OAS1 mRNA expression after 4 h of CDM-3008 or IFNα treatment. After 4 h of treatments with 10 ng/ml
IFNα or 30 μM CDM-3008, similar levels of OAS1 mRNA were induced. The error bars indicate S.D. (n = 3). (C)
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IFNα treatment. To analyze the feedback mechanism and anti-HBV activity of CDM-3008, the
expression levels of individual genes in DMSO-, IFNα-, and CDM-3008-treated cells after 4 h
and 8 h of treatment were compared by qPCR (Fig 5B–5K). SOCS1 showed greater upregula-
tion with CDM-3008 treatment at 4 h and 8 h than with IFNα treatment (Fig 5B). STAT2 was
upregulated by treatment with IFNα and CDM-3008 for 4 h and 8 h compared to DMSO treat-
ment (Fig 5C). IFNAR1 was not downregulated by CDM-3008 treatment, while IFNAR2 was
downregulated with CDM-3008-treatment at 4 h (Fig 5D and 5E), suggesting feedback inhibi-
tion of the receptor for CDM-3008. ISG15 and UPS18, which form a complex that shuts off
downstream signaling of the type I interferon receptor, were upregulated after IFNα and
CDM-3008 treatments compared to DMSO treatment (Fig 5F and 5G). 2’-5’-oligoadenylate
synthetase 1 (OAS1), which mediates pgRNA degradation through RNase L activity, and
ISG20, which degrades RNA/DNA complexes derived from HBV, were upregulated by IFNα
and CDM-3008 treatments compared to DMSO treatment (Fig 5H and 5I). Changes in the
expression levels of APOBEC3 family genes, including APOBEC3F and 3G, both of which are
known to lead to cccDNA degradation, are shown in Fig 5J and 5K. APOBEC3F and 3G were
upregulated after IFNα and CDM-3008 treatments (Fig 5J and 5K), whereas no expression of
APOBEC3A and 3C in PXB cells was detected by PCR. These results suggest that cccDNA can
be degraded by CDM-3008 at least in part through a mechanism similar to the mechanism
associated with IFNα.
To show the molecular mechanism of anti-HBV activity induced by CDM-3008, we per-
formed 3D-PCR for detection of APOBEC3 activity. PXB cells were infected with HBV of
genotype C for 1day and cultured for 28 days; the cells were then treated with 100 μM CDM-
3008 or 10,000 IU/ml IFNα for 7 days. After purification of DNA from the cells, cccDNA was
first amplified by PCR and then the HBx region was amplified by nested PCR (Fig 6A–6C). A
shift to a lower denaturing temperature was only detected in DMSO-treated PXB cells but not
in CDM-3008- or IFNα-treated PXB cells. The PCR products of the HBx region (170 bp) at a
denaturation temperature of 91.2 ˚C were cloned and sequenced (Fig 6D). Approximately 30
clones were sequenced from each conditions. In the DMSO-treated samples, C to T and G to
A transitions at random positions were observed in 21.7% of the clones. In contrast, C to A
transition at position 45 and A to C transition at position 83 were observed in 26.9% of the
clones in the CDM-3008-treated samples, and A to G transition at position 83 was observed in
29.6% of the clones in the IFNα-treated samples. These results suggest that cccDNA molecules
that have undergone random transitions due to APOBEC3 deaminase activity have already
been degraded in CDM-3008- and IFNα-treated PXB cells.
We selected genes that were specifically induced by CDM-3008-treatment, but not by
IFNα. The top 50 most highly expressed genes are shown in Table 1. Serine dehydratase (SDS),
suppressor of cytokine signaling 3 (SOCS3), chromosome 11 open reading frame 96
(C11orf96), serum amyloid A2 (SAA2), and cytokine inducible SH2 containing protein
(CISH) were the most abundantly and specifically induced by CDM-3008-treatment. SOCS3
and CISH are family proteins that inhibit STAT activation [29], and SOCS1 was highly
induced by CDM-3008 compared to IFNα (Fig 5B), suggesting that CDM-3008 efficiently
induces feedback inhibition of the interferon signaling pathway.
Upregulated and downregulated genes. The number of genes whose expression levels were upregulated (orange) or
downregulated (blue) by more than 1.2-fold and for which the P-values determined in the microarray analysis were
less than 0.001 is shown (n = 3). (D) The top 10 canonical pathways most significantly activated (orange) or inactivated
(blue) by IFNα and CDM-3008 were analyzed using the IPA program. The activation z-scores are shown as a heat
map.
https://doi.org/10.1371/journal.pone.0216139.g004
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Fig 5. Comparison of molecules involved in the IFN signaling pathway. (A) Heat map showing genes in the interferon signaling pathway that were significantly
upregulated by more than 1.2-fold (red) and genes that were significantly upregulated by less than 1.2-fold (gray) genes in the interferon signaling pathway. (B-K)
Expression levels of genes associated with interferon signaling. The mRNA expression levels of SOCS1 (B), STAT2 (C), IFNAR1 (D), IFNAR2 (E), ISG15 (F), USP18
(G), OAS1(H), ISG20 (I), APOBEC3F (J), and APOBEC3G (K) were compared at 4 h and 8 h of treatments. The error bars in B-K indicate S.D. (n = 3). �, p< 0.05; ��,
p< 0.01, N.S., not significant (two-tailed t-test) in B-K.
https://doi.org/10.1371/journal.pone.0216139.g005
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CDM-3008-mediated specific expression of SOCS2, SOCS3, CISH, WFDC2, and SLPI was
confirmed by qPCR (Fig 7A–7E).
To analyze feedback inhibition of STAT signaling, the time-dependent expression of OAS1
was analyzed in CDM-3008-treaetd (Fig 8A) and IFNα-treated (Fig 8B) PXB cells. PXB cells
were treated with 30 μM CDM-3008 or 10 ng/ml IFNα for 0, 8, 24, and 48 h. OAS1 expression
levels in CDM-3008 and IFNα-treated cells were increased at 8 h, then decreased at 24 h, and
increased at 48 h (Fig 8A and 8B).
Makowska et al. reported that repeated administration of IFNβ and IFNλ activates the JAK/
STAT pathway without showing feedback inhibition [30]. To show feedback inhibition of
IFN-signaling induced by CDM-3008, PXB cells were stimulated by IFNβ after pretreatment
with CDM-3008 or IFNα. OAS1 expression induced by CDM-3008 was not significantly dif-
ferent with or without IFNβ treatment, whereas OAS1 expression induced by IFNα was
increased by IFNβ treatment (Fig 9). Thus, CDM-3008 induced stronger feedback inhibition
of ISGs expression than IFNα.
To test the additive effect of CDM-3008 and entecavir (ETV), anti-HBV activity was ana-
lyzed in PXB cells that had been treated with 0.1 μM CDM-3008 and/or 0.1 nM ETV (Fig 10).
The concentrations of CDM-3008 and ETV used in the experiment were selected based on the
IC50 of the compounds for anti-HBV activity in PXB cells. Treatment with a combination of
CDM-3008 and ETV significantly reduced the levels of HBV DNA compared with single treat-
ment of CDM-3008 or ETV. Thus, we concluded that CDM-3008 and ETV have an additive
effect.
Discussion
In this study, we show that CDM-3008 had similar anti-HBV activity to IFNα mainly through
ISGs induction. Based on the expression analysis, anti-HBV activity was induced by the RNase
L activity associated with OAS1, the exonuclease activity of ISG20 for degradation of
Fig 6. 3D-PCR analysis for detection of APOBEC3 activity. (A-C) 3D-PCR products (170 bp) amplified from DMSO- (A), CDM-3008- (B), and IFNα- (C) treated
PXB cells at different denaturation temperatures (80–92 ˚C) were separated by 2% agarose gel electrophoresis and visualized. (D) The 3D-PCR products obtained at a
denaturing temperature of 91.2 ˚C were sequenced, aligned with the consensus sequence, and numbered. Mutations are shown as inverted letters.
https://doi.org/10.1371/journal.pone.0216139.g006
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Table 1. Top 50 genes specifically upregulated by CDM-3008 treatment.
Average
Rank Gene ID Symbol Entrez Gene Name Type(s) IFN /DMSO CDM /DMSO
1 10993 SDS serine dehydratase enzyme 1.02 2.18
2 9021 SOCS3 suppressor of cytokine signaling 3 phosphatase 1.03 2.14
3 387763 C11orf96 chromosome 11 open reading frame 96 other 0.95 2.06
4 6289 SAA2 serum amyloid A2 other 1.05 1.95
5 1154 CISH cytokine inducible SH2 containing protein other 0.98 1.93
6 5596 MAPK4 mitogen-activated protein kinase 4 kinase 1.10 1.75
7 1723 DHODH dihydroorotate dehydrogenase (quinone) enzyme 0.97 1.73
8 5320 PLA2G2A phospholipase A2 group IIA enzyme 1.02 1.72
9 5105 PCK1 phosphoenolpyruvate carboxykinase 1 kinase 1.14 1.69
10 6288 SAA1 serum amyloid A1 transporter 1.02 1.64
11 3934 LCN2 lipocalin 2 transporter 1.03 1.64
12 9214 FAIM3 Fc fragment of IgM receptor other 1.02 1.61
13 644945 KRT16P3 keratin 16 pseudogene 3 other 1.08 1.55
14 5292 PIM1 Pim-1 proto-oncogene, serine/threonine kinase kinase 0.93 1.49
15 10344 CCL26 C-C motif chemokine ligand 26 cytokine 1.00 1.48
16 9510 ADAMTS1 ADAMTS type 1 motif 1 peptidase 0.98 1.48
17 4837 NNMT nicotinamide N-methyltransferase enzyme 1.04 1.47
18 11238 CA5B carbonic anhydrase 5B enzyme 1.02 1.47
19 14415 GAD1 glutamate decarboxylase 1 enzyme 1.11 1.45
20 220108 FAM124A family with sequence similarity 124 member A other 1.11 1.45
21 2243 FGA fibrinogen alpha chain other 1.08 1.45
22 7004 TEAD4 TEA domain transcription factor 4 transcription 1.11 1.43
23 3929 LBP lipopolysaccharide binding protein transporter 1.01 1.43
24 8740 TNFSF14 TNF superfamily member 14 cytokine 0.91 1.42
25 79689 STEAP4 STEAP4 metalloreductase enzyme 1.02 1.42
26 10406 WFDC2 WAP four-disulfide core domain 2 other 1.03 1.42
27 10912 GADD45G growth arrest and DNA damage inducible γ other 0.96 1.41
28 23151 GRAMD4 GRAM domain containing 4 other 0.97 1.41
29 1116 CHI3L1 chitinase 3 like 1 enzyme 0.99 1.41
30 7043 TGFB3 transforming growth factor beta 3 growth factor 1.00 1.41
31 27289 RND1 Rho family GTPase 1 enzyme 0.96 1.40
32 283777 FAM169B family with sequence similarity 169 member B other 1.00 1.39
33 6446 SGK1 serum/glucocorticoid regulated kinase 1 kinase 1.01 1.38
34 57509 MTUS1 microtubule associated scaffold protein 1 other 0.98 1.38
35 53905 DUOX1 dual oxidase 1 enzyme 1.01 1.38
36 7504 NA X-linked Kx blood group transporter 1.00 1.38
37 642273 FAM110C family with sequence similarity 110 member C other 1.08 1.37
38 10507 SEMA4D semaphorin 4D receptor 1.12 1.37
39 8829 NRP1 neuropilin 1 receptor 1.09 1.37
40 3726 JUNB JunB proto-oncogene, AP-1 transcription factor subunit transcription 1.11 1.36
41 3283 HSD3B1 hydroxy-δ-5-steroid dehydrogenase, 3β- and steroid δ-isomerase 1 enzyme 0.99 1.36
42 6590 SLPI secretory leukocyte peptidase inhibitor other 1.07 1.36
43 3394 IRF8 interferon regulatory factor 8 transcription 1.08 1.36
44 10957 PNRC1 proline rich nuclear receptor coactivator 1 other 1.06 1.36
45 388125 C2CD4B C2 calcium dependent domain containing 4B other 0.98 1.36
46 89870 TRIM15 tripartite motif containing 15 other 0.97 1.35
(Continued)
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Table 1. (Continued)
Average
Rank Gene ID Symbol Entrez Gene Name Type(s) IFN /DMSO CDM /DMSO
47 6347 CCL2 C-C motif chemokine ligand 2 cytokine 1.09 1.35
48 10509 SEMA4B semaphorin 4B other 1.03 1.34
49 64856 VWA1 von Willebrand factor A domain containing 1 other 0.99 1.34
50 116372 LYPD1 LY6/PLAUR domain containing 1 GPCR 0.97 1.34
The gene ID, symbol, Entrez gene name, type of gene, and average expression level are indicated in the table. Expression levels of genes in IFNα- and CDM-3008-treated
cells were divided by the expression levels of genes in DMSO-treated cells. Genes that were specifically upregulated in CDM-3008-treated cells and not in IFNα-treated
cells were selected, and the top 50 most highly expressed genes are shown.
https://doi.org/10.1371/journal.pone.0216139.t001
Fig 7. qPCR analysis of CDM-3008-specific genes. (A-E) mRNA expression levels of SOCS2 (A), SOCS3 (B), CISH (C),
WFDC2 (D), and SLPI (E) were compared at 4 h and 8 h of treatments. The error bars in A-E indicate S.D. (n = 3). �,
p< 0.05; ��, p< 0.01; N.S., not significant (two-tailed t-test) in A-E.
https://doi.org/10.1371/journal.pone.0216139.g007
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RNA-DNA complexes, and the deaminase activity of APOBEC3 family proteins for cccDNA
degradation [16,31,32].
CDM-3008 induced higher levels of genes involved in feedback inhibition such as SOCS1,
SOCS2, SOCS3, and CISH than IFNα [29]. CDM-3008 suppresses IFNAR2 expression. CDM-
3008 and IFNα induced similar expression levels of ISG15 and USP18 [33]. Thus, CDM-3008
can effectively inhibit interferon signaling by suppressing its receptor and downstream
signaling.
Fig 8. Time course of OAS1 expression after CDM-3008 or IFNα treatment. (A-B) OAS1 mRNA expression levels
were compared after 0, 8, 24 and 48 h of CDM-3008 (A) and IFNα (B) treatment. The error bars in A, B indicate S.D.
(n = 3). �, p< 0.05; ��, p< 0.01 (two-tailed t-test) in A, B.
https://doi.org/10.1371/journal.pone.0216139.g008
Fig 9. OAS1 expression of IFNβ-treated cells pre-incubated with CDM-3008 or IFNα. PXB cells were pretreated
with 30 μM CDM-3008 (CDM) or 10 ng/ml IFNα for 24 h and then treated with 10 ng/ml IFNβ for 4 h. mRNA
expression levels of OAS1 were compared. The error bars indicate S.D. (n = 3). �, p< 0.05; ��, p< 0.01; N.S., not
significant (two-tailed t-test).
https://doi.org/10.1371/journal.pone.0216139.g009
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Several acute phase proteins were involved in CDM-3008-induced genes such as SAA1,
SAA2, WFDC2, and SLPI, as shown in Table 1. SAA1 and SAA2 expression levels are
increased with infection, inflammation, and injury. SAA has cytokine-like activity in the
inflammatory response and induces cytokines and chemokines. SAA is highly expressed in
HCC associated with HBV [34]. Thus, SAA1 and SAA2 may contribute to inflammation and
innate immunity resulting from HBV.
Anti-viral peptides are enhanced in their expression and secreted into the extracellular
space in response to acute inflammation. WFDC2 and SLPI were upregulated by CDM-
3008-treatment. WFDC2 and SLPI have a whey acidic protein (WAP) motif. WAP motif-con-
taining peptides are part of a family containing WFDC2, SLPI, and elafin and are often associ-
ated with anti-viral and anti-bacterial activities [35,36]. Elafin is secreted form epithelial cells
and shows anti-HIV-1 activity [37,38]. WAP-motif containing peptides are possible anti-HBV
factors in the innate immune system.
In this study, the donor of the hepatocytes used in the assays was changed after the microar-
ray analysis was conducted. This occurred because the supplier of the hepatocytes, PhoenixBio
Inc., prepares human liver chimeric mice from new donors approximately every 6 years. The
expression levels of ISGs after CDM-3008 and IFNα treatment differed depending on the
Fig 10. Additive effect of CDM-3008 and entecavir on anti-HBV activity. Primary cultured human hepatocytes
(PXB cells) were infected with HBV genotype C for 1day and cultured for 28 days; the cells were then treated with
0.1 μM CDM-3008 and/or 0.1 nM entecavir (ETV) for 7 days. HBV DNA copies in PXB cells were measured by qPCR.
The error bars indicate S.D. (n = 3). �, p< 0.05 (two-tailed t-test).
https://doi.org/10.1371/journal.pone.0216139.g010
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donor of the hepatocytes. Fig 4B shows that OAS1 expression levels in CDM-3008- and IFNα-
treated cells were 4 times higher than the levels in control DMSO-treated cells when an old
donor of hepatocytes was used, while Fig 5H shows that OAS1 expression in CDM-3008- and
IFNα-treated cells was approximately 30 times higher than in control DMSO-treated cells
when a new donor of hepatocytes was used. The response to IFNα and ribavirin in hepatitis C
virus-infected patients is associated with a single-nucleotide polymorphism in the IL28 gene
[39]. Thus, the response to CDM-3008 and IFNα appears to different depending on genetic
variation in the donor.
Niu et al. reported that established HBV infection does not significantly modulate the tran-
scriptional response to various innate immune stimuli [40]. In this study, difference more than
1.2-fold in the expression levels of host factors was not observed when HBV-infected and non-
infected PXB cells were analyzed by microarray. In our experiments, PXB cells were infected
with 3 genome equivalents of HBV and cultured for 30 days. The number of HBV copies/cell
was calculated to be approximately 1 copy/cell (Fig 1). It is expected that 1 copy of HBV per
hepatocyte would have little effect on host factors. In addition, PXB cells were cultured for 30
days after infection with HBV; the innate immune response would be expected to occur during
the early stage of infection and to decrease during the 30 days following infection.
CDM-3008 treatment of PXB cells suppressed cccDNA and HBeAg, which is thought to be
a marker for cccDNA (Fig 1) [41,42]. APOBEC3F and 3G were highly expressed in PXB cells
after CDM-3008 treatment. Thus, cccDNA could be degraded due to the deaminase activity of
APOBEC3F and 3G. To confirm APOBEC3 activity, we performed 3D-PCR. Random C to A
and G to T transitions were detected in DMSO-treated PXB cells, while C to A and A to C
transitions at positions 45 and 83 and A to G transition at position 83 were detected in CDM-
3008- and IFNα-treated PXB cells, respectively (Fig 6D). These results suggest that cccDNA
molecules that have undergone random transitions due to APOBEC3 deaminase activity have
already been degraded in CDM-3008- and IFNα-treated PXB cells after exposure of the cells to
the treatment for 7 days. Kitamura et al. showed that transitions induced by APOBEC3G were
mainly G to A transitions [43]. The transitions at position 83 induced by CDM-3008 and
IFNα appear to differ from the transitions induced by APOBEC3 family proteins, indicating
that the other modifying enzymes specifically induced by CDM-3008 and IFNα could be
involved in cccDNA modification.
Both CDM-3008 and IFNα exert their anti-HBV activity primarily through activation of
the JAK/STAT pathway and ISGs induction. CDM-3008 is a small chemical compound that is
available for oral administration and can be produced at low cost, indicating an advantage of
CDM-3008 over IFNα [21]. Orally administered CDM-3008 is thought to be absorbed from
the intestine and delivered to the liver through the portal vein. Thus, CDM-3008 could be effi-
ciently delivered to the liver, reducing side effects compared to intravenously injected IFNα.
Orally administered CDM-3008 can be used with the other newly developing orally adminis-
tered drugs, such as nucleotide analogues and capsid allosteric modulators. CDM-3008
induced ISGs expression only through IFNAR2, while IFNα induced ISGs expression through
a heterodimer of IFNAR1 and IFNAR2 (Fig 2). Thus, IFNAR1 downstream signaling associ-
ated with side effects could be suppressed. CDM-3008 showed relatively higher feedback inhi-
bition of JAK/STAT signaling than IFNα and easily controlled JAK/STAT activity. This
feature may suggest an approach to regulating side effects. However, CDM-3008 has problems
with solubility and metabolic stability that may affect its use as a drug. We have initiated a
structure-activity relationship study to improve the solubility of CDM-3008. CDM-3032, a
derivative of CDM-3008, shows improved solubility and metabolic stability in both mouse and
human hepatic microsomes [44]. We are continuing a further structure-activity relationship
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study of CDM-3008 with a goal of improving its solubility, metabolic stability, and anti-HBV
activity and reducing its potential side effects associated with IFNα.
Conclusions
CDM-3008 is a small chemical compound that exerts anti-HBV activity mainly through the
interferon signaling pathway; its activity includes induction of the expression of ISGs and
APOBEC3 family proteins. Feedback inhibition of interferon signaling induced by CDM-3008
appears to be stronger than that induced by IFNα. CDM-3008 is potentially available for oral
administration and cotreatment with nucleotide analogs and can be produced at a low cost,
indicating advantages of CDM-3008 over IFNα.
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